Table 3.

Rate and volume change in fGM, and fWM loss and fCSF increase, in healthy controls, and diagnostic categories of gene‐positive subjects in the longitudinal study

Diagnostic categories	n	Average follow‐up months	GM			WM			CSF
			Rate of change	(mL)/year loss	P	Rate of change	(mL)/year loss	P	Rate of change	(mL)/year increase	P
Control	15	13	–0.001	–0.01	ns	–0.001	–0.02	ns	0.003	0.05	ns
True preclinical	8	18	–0.001	–0.03	ns	–0.048	–0.87	0.0158	0.014	0.25	ns
Soft signs	3	18	–0.130	–2.34	0.0793	0.001	0.02	ns	0.087	1.56	0.0891
Stage 1	5	19	–0.039	–0.75	0.0437	–0.018	–0.35	ns	0.058	1.11	0.0223
Stage 2	8	20	–0.064	–1.24	0.0465	0.011	0.22	ns	0.051	1.01	0.0141
Stage 3	8	23	–0.050	–1.15	ns	–0.045	–1.04	ns	0.094	2.17	0.0139

The longitudinal analysis of HD subjects and controls showed a variable time‐ and stage‐dependent brain‐tissue volume change in HD.

Last stage follow‐ups are missing due to the small size of the cohort.